Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
1998

Comparing Two Chemotherapy Regimens for Testicular Cancer

Sample size: 84 publication Evidence: moderate

Author Information

Author(s): R de Wit, G Stoter, DTh Sleijfer, JP Neijt, WW ten Bokkel Huinink, L de Prijck, L Collette, R Sylvester

Primary Institution: Rotterdam Cancer Institute and University Hospital

Hypothesis

Is ifosfamide superior to bleomycin in combination with cisplatin and etoposide for treating intermediate-prognosis metastatic testicular non-seminoma?

Conclusion

The study found no significant difference in efficacy between the two chemotherapy regimens, but VIP was more toxic.

Supporting Evidence

  • Complete response rates were similar for both treatments, with 79% for BEP and 74% for VIP.
  • After surgery, 82% of patients on BEP and 80% on VIP were rendered disease-free.
  • VIP showed significantly higher toxicity, with 89% experiencing severe leucocytopenia compared to 37% on BEP.

Takeaway

Doctors wanted to see if a new medicine was better than an old one for treating a type of cancer, but they found out they worked about the same.

Methodology

Patients were randomized to receive either BEP or VIP chemotherapy and were monitored for response and toxicity.

Limitations

The study was prematurely discontinued due to data from a competing study showing no improved effectiveness of VIP compared to BEP.

Participant Demographics

Patients had intermediate-prognosis metastatic testicular non-seminoma.

Statistical Information

P-Value

0.62

Confidence Interval

95% CI 74-96%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication